1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Rheumatoid Arthritis [2017]

Rheumatoid Arthritis [2017]

  • April 2017
  • ID: 4883737
  • Format: PDF
  • By Firstword Pharma


Table of Contents

How are biosimilar anti-TNFs faring? Will your brand be affected?

After several years on the US market, the availability of Pfizer’s Xeljanz in the EU is generally welcomed by KOLs; however, it now looks like Eli Lilly/Incyte’s Olumiant (baricitinib) is likely to be launched first.

KOL’s weigh in on Olumiant’s safety and efficacy, as well as its chances to become the market leader in the JAK inhibitor space. Meanwhile, KOLs also discuss how AbbVie’s upadacitinib (ABT 494) and Galapagos/Gilead Sciences’ filgotinib shape up in an ever competitive JAK inhibitor market.

Experts also give their views on how biosimilar anti-TNFs are faring and what lies ahead for branded anti-TNFs, as well as providing insights into how Sanofi/Regeneron’s Kevzara (sarilumab) shapes up in the IL-6 inhibitor space. Twelve US and EU KOLs offer their candid insights on these issues and more.

Top Takeaways
- An increasing number of biosimilar anti-TNFs are being approved. How do KOLs view these products and how do they envisage their usage in the future?
- Benepali, a biosimilar etanercept, is available in several EU countries. But what impact has this biosimilar had on Enbrel prescribing?
- How do KOLs view Olumiant’s recent EU approval? And can Pfizer’s Xeljanz fend off competition from this product?
- Actemra/RoActemra is regarded as a highly effective therapy. But are their differences in US/EU prescribing and how is the product expected to be prescribed in the future?
- How does Kevzara shape up against Actemra/RoActemra? KOLs rate the potential of Kevzara and provide insights as to how it could take a slice of the anti-IL6 market.
- Upadacitinib and filgotinib will be late-to-market. What would these products need to show in order to compete effectively?
- KOLs discuss future trends that may play a part in shaping the future treatment of RA. What are KOLs’ thoughts on future general trends and how will these impact RA treatment in the future.

“I followed tocilizumab for a long time and I was involved in some of their initial trials, and so I think it’s a very good drug and it’s safe. It has consistently shown very good results in clinical trials including a direct comparison with adalimumab.” EU Key Opinion Leader

“ABT 494 [upadacitinib] is yet another JAK inhibitor. The JAK inhibitor market will become quite saturated in the future. Everyone is developing a JAK inhibitor, whether it be JAK1, JAK2 or JAK 3 etcetera. We still don’t know what difference blocking these receptors will make anyway. I don’t think all of them will survive.” US Key Opinion Leader

TNF inhibitors:
- Humira (adalimumab; AbbVie)
- Enbrel (etanercept; Amgen/Pfizer)
- Remicade (infliximab; Janssen Biotech/Merck & Co.)
- Cimzia (certolizumab pegol; UCB)
- Simponi (golimumab; Janssen Biotech/Merck & Co.)
- Actemra/RoActemra (tocilizumab; Roche)
- Orencia (abatacept; Bristol-Myers Squibb)
- Rituxan/MabThera (rituximab; Roche/Biogen)
- Xeljanz (tofacitinib; Pfizer)
- Anti-TNF biosimilars (e.g. Remsima/Inflectra, Benepali)

Pipeline Therapies
- Kevzara (sarilumab; Sanofi/Regeneron)
- sirukumab (CNTO 136; Janssen/GlaxoSmithKline)
- olokizumab (R-Pharm/UCB)

Earlier stage:
- piclidenoson (CF 101; Can-Fite)
- mavrilimumab (CAM 3001; AstraZeneca)

KOLs from North America
- Prof Michael E Weinblatt, MD. Professor of Medicine at Harvard Medical School. Dr. Weinblatt serves as Co-director of Clinical Rheumatology at the Brigham and Women's Hospital.
- Dr Petros Efthimiou, MD. Associate Chief of Rheumatology at New York Methodist Hospital and an Associate Professor of Medicine and Rheumatology at Weill Cornell Medical College.
- Prof Fleischmann, MD. Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas and co-Medical Director of the Metroplex Clinical Research Center in Dallas, TX.

KOLs from Europe
- Prof Paul Emery. Arthritis Research UK Professor of Rheumatology and Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine and the - Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust, UK.
- Prof Tore K Kvien. Professor of Rheumatology at the University of Oslo and Head of the Department of Rheumatology at Diakonhjemmet Hospital, Oslo, Norway.
- Prof Ronald F van Vollenhoven. Director of the Amsterdam Rheumatology and Immunology Center ARC and Chief of the Department of Rheumatology and Clinical Immunology at the AMC and of the Department of Rheumatology at VUMC (VU University Medical Center) in Amsterdam, the Netherlands.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on